ArticleBMC genomics2026
Multi-omics analysis reveals that puerarin modulates the gut-liver axis to improve hepatic health in aged laying hens.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAge-related hepatic metabolic dysfunction significantly impairs the health and productivity of laying hens. Puerarin (Pue), a natural isoflavone, exhibits diverse pharmacological activities relevant to liver and gut health. Our previous work demonstrated that dietary supplementation with Pue improved laying performance and egg quality, while reducing the feed conversion ratio in aged laying hens. Building on these findings, we employed an integrated multi-omics approach to investigate whether Pue exerts hepatoprotective effects by restoring gut-liver axis homeostasis, thereby supporting liver function and potentially extending the production performance of aged laying hens.
resultsPue supplementation significantly ameliorated hepatic pathological changes, including vacuolar degeneration, lipid accumulation, fibrosis, and apoptosis. Additionally, Pue reduced malondialdehyde levels and enhanced the activities of total antioxidant capacity, glutathione peroxidase, and catalase in the liver. Transcriptomic and serum metabolomic analyses revealed that Pue upregulated CYP7B1 and downregulated CYP7A1, thereby altering bile acid profiles without affecting total bile acid levels. Molecular dynamics simulations further demonstrated that Pue exhibits a stronger binding affinity to CYP7B1 than to CYP7A1. Although Pue treatment did not significantly alter the α-diversity and β-diversity of the gut microbiota, it significantly increased the abundance of Rikenellaceae_RC9_gut_group and enhanced butyric acid production, which in turn elevated the expression of intestinal tight junction proteins (Claudin-1 and Claudin-3). Multi-omics correlation analysis confirmed the regulatory network between the gut and liver.
conclusionsPue enhances hepatic health in aged laying hens by modulating bile acid metabolism and altering gut microbiota composition, primarily through gut-liver axis regulation as revealed by integrated multi-omics analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.